BioCentury

12:03 AM GMT, May 29, 2010
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Company News

FDA questions motavizumab safety

FDA questioned the risk-benefit profile of motavizumab in briefing documents posted ahead of Wednesday's Antiviral Drugs Advisory Committee meeting

Read the full 193 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.